Floatz logo

Cilofexor

Primary Biliary Cholangitis

Gilead SciencesSmall moleculePhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the Primary Biliary Cholangitis cohort.

Asset / SponsorPhaseRating
URSODEOXYCHOLIC ACID
Xijing Hospital of Digestive Diseases
Phase 4A
Saroglitazar
Zydus Therapeutics Inc.
Phase 3BB
Fenofibrate
Xijing Hospital of Digestive Diseases
Phase 3BB
Mbx-8025
Gilead Sciences
Phase 3BB
cs0159
Cascade Pharmaceuticals, Inc
Phase 3BB

View all 50 →

Same molecule, other indications

Cilofexor is also rated in:

metabolic dysfunction-associated steatohepatitisDormant
B
Indicative ·
63 / 100
View asset →
primary sclerosing cholangitisDormant
B
Indicative ·
59 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →